Abstract:Objective: To explore the clinical features, surgical treatment, and effectiveness of neurofibromas associated with neurofibromatosis type 1 (NF1). Methods: A clinical data of 41 patients with NF1 admitted between December 2018 and April 2024 was retrospectively analyzed. There were 15 males and 26 females, with an average age of 27.5 years (range, 5-61 years). Only one type of neurofibroma existed in 3 patients and the rest of the patients had more than two types of neurofibromas. Fourteen patients had total resection of multiple cutaneous neurofibromas (CNF). Eighteen patients of diffuse neurofibromas underwent total, near-total, or subtotal resection. Among the 13 patients of localized nodular neurofibromas, 9 of benign tumors underwent total sub-capsular resection and 4 of malignant peripheral nerve sheath tumor (MPNST) underwent maginal resection, and only 1 underwent postoperative radiotherapy and chemotherapy. Among the 15 patients of plexiform neurofibromas (PNF), 5 patients underwent both superficial and deep PNF resection, 2 underwent the superficial PNF resection, and 8 underwent the large nodular lesions in the deep PNF resection. There were 8 MPNST, of which 7 cases underwent total sub-capsular resection and large tumor capsule resection under neurophysiological monitoring, and 1 case with the tumor located on the top of the head underwent wide resection and skin grafting. One patient underwent proton knife therapy after surgery, 2 patients did not receive radiotherapy, and the remaining patients received conventional radiotherapy. Results: All patients were followed up after surgery, and the follow-up time was 3-66 months, with an average of 25.0 months. Patients with CNF recovered satisfactorily after surgery, and there was no recurrence during follow-up. Patients with diffuse neurofibromas relieved preoperative symptoms after surgery. Three patients with diffuse neurofibromas located in the head and face recurred during follow-up. The patients with benign localized nodular neurofibromas recovered well after surgery, and only 1 patient had transient regional neuralgia after surgery. Among the patients with MPNST, 2 patients died of recurrence and lung metastasis, while the remaining 2 patients had no recurrence and metastasis during follow-up. All preoperative symptoms disappeared in patients with benign PNF, and no tumor recurrence was observed during follow-up. Two patients with PNF located in the brachial plexus had difficulty in shoulder abduction after surgery, 1 patient with PNF located in vagus developed hoarseness after surgery. Among the 8 patients with MPNST in PNF, 1 died of lung metastases and 1 died of systemic failure. The remaining 6 patients were in stable condition during follow-up, and no tumor recurrence or metastasis was observed. Conclusion: According to the clinical features of neurofibromas in patients with NF1, choosing appropriate surgical approaches can obtain good effectiveness. Because of the difficulty of completely resection, diffuse neurofibromas, especially those located in the head and face, are prone to recurrence after surgery. MPNST has the worst prognosis, high incidence of recurrence/metastasis, and short survival period. Total resection combined with radiotherapy can decrease local recurrence.

Role and mechanism of mast cells in neurofibroma

Role of nerves in neurofibromatosis type 1-related nervous system tumors

Tumorigenesis in neurofibromatosis type 1: role of the microenvironment

RAS and beyond: the many faces of the neurofibromatosis type 1 protein

[Progress and prospects in diagnosis and treatment of neurofibromatosis type 1]

Advances in Diagnosis and Treatment of Neurofibromatosis Type 1

The impact of host immune cells on the development of neurofibromatosis type 1: The abnormal immune system provides an immune microenvironment for tumorigenesis

Translating current basic research into future therapies for neurofibromatosis type 1

A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor

Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer

A Novel Mutation in NF1 Gene of Patient with Neurofibromatosis Type 1: A Case Report and Functional Study

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis

Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?

Conditional deletion of Pten tumor suppressor gene and activation of K Ras oncogene result in the development of Neurofibromatoses

Advancement in research and therapy of NF1 mutant malignant tumors

Impacts of NF1 Gene Mutations and Genetic Modifiers in Neurofibromatosis Type 1

Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1

[Clinical features and surgical treatments of neurofibromas associated with neurofibromatosis type 1]

Mechanistic insights from animal models of neurofibromatosis type 1 cognitive impairment

[Progress in neurosurgical treatment of neurofibromatosis type 1]

PD-L1 Expression and Tumor Infiltrating Lymphocytes in Neurofibromatosis Type 1-Related Benign Tumors and Malignant Peripheral Nerve Sheath Tumors: an Implication for Immune Checkpoint Inhibition Therapy